Question · Q1 2022
Zegbeh Jallah followed up on the correlation between SDMA reduction and tumor response, asking about patient variability and whether clinical combination data might be available to influence GSK's decision.
Answer
Chief Scientific Officer Michael White reiterated that preclinical data suggests getting below a threshold of SDMA is key, rather than the percentage change. CEO & President Yujiro Hata noted that clinical tumor PD data is still limited for assessing variability and confirmed that clinical combination data is not a requirement for the GSK option package.